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Background: Breast cancer is currently the second leading cause of cancer-related death in the 
United States and the most commonly diagnosed cancer among women. Approximately 85,000 
new cancer cases per year can be attributed to obesity, a known risk factor for breast cancer that 
alters key physiological pathways linked to tumorigenesis and metastasis. In the obese state, 
adipose tissue undergoes remodeling which promotes chronic, low-grade inflammation. This 
inflammatory response can result in increased serum levels of several proteins involved in cellular 
growth, proliferation and survival that are also known to support breast cancer progression and 
metastasis. In addition, obesity-associated adipocytes are known to secrete pro-inflammatory 
cytokines which have been indicated as potential mediators in the progression of breast cancer. 
Targeting inflammation using non-steroidal anti-inflammatory drugs (NSAIDs), such as Sulindac, 
has shown promising results in decreasing breast cancer recurrence; however, additional research 
is necessary to assess their efficacy in obesity-associated breast cancer models. This study 
therefore aims to investigate the role of obesity-associated changes in the adipose secretome in 
driving breast cancer progression and metastasis. 
 
Methods: To model the response of breast cancer cells to alterations in the adipose secretome in 
vitro, we cultured multiple metastatic breast cancer cell lines in fat conditioned media (FCM) 
derived from the mammary fat pads of female C57Bl/6 mice on Control, diet-induced obesity 
(DIO), and DIO+Sulindac diets. Phenotypic assays including MTT and wound-healing assays 
were conducted to determine proliferative and migratory differences between the varying FCM 
diet conditions. Following characterization, pro-inflammatory mediators were identified using a 
Luminex assay and gene expression analysis in mammary adipose tissue. The efficacy of Sulindac 
as a strategy for mitigating obesity-associated adipose tissue inflammation and breast cancer 
progression was evaluated.  
 
Results: Treatment with FCM, regardless of the diet group from which the FCM was obtained, 
increased both cell viability and migration of multiple breast cancer cell lines in vitro, indicating 
its role in promoting cancer cell proliferation and metastasis. No significant differences were 
observed between the Control, DIO and DIO+Sulindac diet conditions following phenotypic 
analysis; however, gene expression and multiplexed cytokine analyses revealed increased 
concentrations of pro-inflammatory cytokines in the DIO conditions relative to both control and 
DIO+Sulindac conditions.  
 
Conclusions: Our FCM studies suggest that obesity-associated cytokine changes in the adipose 
tissue secretome, and concomitant transcriptional changes in the adipose tissue itself, increase the 
proliferative and metastatic potential of various breast cancer cell lines. Supplementation with 
Sulindac may offset the procancer effects of obesity by reducing proinflammatory cytokines in the 
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Breast Cancer Prevalence and Mortality 
Cancer is a worldwide public health concern with rapidly increasing incidence and 
mortality rates1. In 2018 alone, there were 18.1 million new reported cancer cases and 9.1 million 
cancer deaths2. Among women, breast cancer is the most commonly diagnosed cancer and the 
second leading cause of cancer-related death in the United States2. Breast cancer starts as a 
localized disease but has the capacity to spread to local lymph nodes and distant organs, a process 
known as metastasis. In breast cancer, metastatic spread most commonly occurs to the  lungs, liver, 
bones, or brain, all of which present significant clinical challenges for breast cancer treatment3–5. 
Although advances in treatment and early mammographic detection reported between 1989 and 
2017 demonstrated a 40% decline in overall breast cancer deaths, metastasis remains one of the 
largest contributors to breast cancer mortality6. Importantly, patients with Stage I, localized breast 
cancers have a nearly 100% five-year survival rate, whereas patients with Stage IV, metastatic 
breast cancers have only a 27% five-year survival rate7. As there is no cure for metastatic breast 
cancer, current treatment options must instead focus on managing recurrence and progression of 
the disease, highlighting the importance of research in this field.   
Obesity and Breast Cancer  
Obesity is an epidemic affecting over one-third of the entire United States adult population 
and is an established risk factor for many breast cancer subtypes8,9. Approximately 85,000 new 
cancer cases per year can be attributed to obesity, 9% of which are breast cancer cases10. Not only 
are obese women at a higher risk of developing breast cancer, but they are more likely to have 
greater tumor burden at time of diagnosis and more disseminated recurrence following remission 
than non-obese women8,11–14. Furthermore, studies suggest that obese patients are often less 
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sensitive to chemotherapy treatment compared to nonobese patients15–17. The higher body mass 
index of obese individuals (BMI ≥ 30) has also been associated with greater risk of mortality 
following breast cancer diagnosis, with some studies indicating as much as a 3-fold increased risk 
compared to normal weight individuals18–21. Interestingly, even women with a normal-range BMI 
but high body fat composition have been shown to exhibit similar health risks to obese individuals, 
due to poor adipose tissue quality and metabolic abnormalities22. 
On a cellular level, an influx of excess energy in the obese state is converted to 
triacylglycerol and stored in adipose tissue depots. Adipose tissue accommodates for the 
accumulation of triacylglycerol primarily through the growth of preexisting adipocytes, a process 
known as adipose hypertrophy23. This chronic positive energy balance and atypical expansion of 
adipocytes promotes adipocyte hypoxia and necrosis, which has previously been shown to drive 
nearby cells cells into a dynamic process known as epithelial-to-mesenchymal transition (EMT)23–
25. Cells that undergo EMT experience multiple molecular changes that enable them to transition 
from polarized, epithelial cells into mobile, mesenchymal cells26,27. These changes enhance the 
cell’s migratory capacity, stemness, invasiveness and resistance to apoptosis, which thereby 
contribute to cancer progression and metastasis27,28. Previous work in our lab utilizing obese mouse 
models have demonstrated these phenotypic changes using MMTV-Wnt-1 basal-like breast 
cancer26. Gene expression analyses of tumors from lean and obese mice displayed significant 
upregulation of pro-tumorigenic pathways in obese-state tumors compared to lean, specifically 
those involved in regulating EMT. Additionally, serum isolated from obese mice stimulated 




Numerous clinical studies have further investigated the prognostic significance of tumor 
cell invasion into peritumoral adipose tissue29,30. Adipose tissue invasion by breast cancer cells has 
been found to be positively correlated with tumor burden, metastatic spread, and poor patient 
outcome31,32. Strikingly, a 2008 study revealed axillary lymph node metastases in 40.7% of 
patients with adipose tissue invasion by breast cancer cells. Only 11.3% of patients without adipose 
tissue invasion, however, developed metastases32. Experimental data report a similar oncogenic 
relationship between adipose tissue and tumor cells—mice injected with mammary carcinoma 
cells demonstrated increased cell growth in adipocyte-rich environments, as well as more efficient 
metastatic spread33,34. Although both obesity and adipose tissue have been shown to alter cancer 
outcomes by modifying many pathways involved in tumorigenesis and metastasis, the precise 
mechanisms modeling these responses remain illusive25,35.  
Obesity-Associated Adipose Tissue Inflammation 
Despite the gap in knowledge surrounding the obesity-breast cancer link, one well-known 
hallmark of dysfunctional adipose tissue remodeling in the obese state is the establishment of a 
pro-inflammatory microenvironment24. This inflammatory response, stimulated in part by 
infiltrating cells such as macrophages, dendritic cells and fibroblasts, can result in increased serum 
levels of several proteins involved in cancer growth and progression36. In addition, it has been 
suggested that the proximity of adipocytes to growing tumors facilitates metabolic symbiosis—
the adipocytes drive a metabolic shift in cancer cells to increase utilization of available fuel 
sources, thereby supporting tumor growth37,38. As a part of this adipocyte-cancer crosstalk, obesity-
associated adipocytes are known to secrete pro-inflammatory cytokines, chemokines, and growth 
factors which have been previously indicated as potential mediators in the progression of breast 
cancer39. When overexpressed in adipose tissue, one of these pro-inflammatory cytokines, 
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interleukin (IL)-6, has been noted to increase tumor cell differentiation and angiogenesis, aiding 
in cancer cell development40–42.  There is experimental evidence that the overexpression of IL-6 in 
tumor-surrounding adipocytes may directly mediate the invasive activity of metastatic 4T1 breast 
cancer cells in murine models, and when depleted with anti-IL-6 antibodies, these invasive 
capabilities are decreased34,43–45. Importantly, human models have demonstrated a similar 
response, as high levels of serum IL-6 has been clinically correlated with larger tumor size and 
faster disease progression46.  
Sustained obesity also increases the production of prostaglandins—a group of 
inflammatory signaling molecules derived from long-chain fatty acids that are associated with 
enhanced cancer cell survival, migration, and immunosuppression47. Analyses of breast tissue 
from obese women have demonstrated increased levels of prostaglandins compared to lean 
women48. Furthermore, elevated intratumoral prostaglandin levels in the obese state have been 
linked to tumor progression of multiple cancer cell lines by directly inhibiting the proliferative 
functions of CD4+ and CD8+ T cells49–51. This inhibition blocks adaptive immunity, and 
subsequently drives CD4+ differentiation into regulatory T cells,  further suppressing the immune 
response49,50. One specific eicosanoid thought to contribute to immune evasion, Prostaglandin E2 
(PGE2), has also been detected in high amounts in malignant breast tumors52. PGE2 has recently 
emerged as a mediator of oncogenic signaling pathways in breast cancer tumor cells, contributing 
to regulatory T cell proliferation, impaired NK cell viability, and M2 macrophage promotion, all 
of which support immune suppression and subsequent tumorigenesis53,54. Additionally, migratory 
murine C3L5 and human MDA-MB-231 breast cancer cells show elevated PGE2 levels in 




 The accumulation of PGE2 in breast cancer models is in part stimulated by aberrant 
upregulation of the enzymes necessary for its production: Cyclooxygenase 1 and 2 (COX-1, and 
COX-2)55. The current body of evidence suggests that these enzymes are regulated by growth 
factors and pro-inflammatory cytokines, such as IL-6, that are secreted by the adipose tissue under 
obese conditions57. Moreover, overexpression of the inducible COX-2 enzyme has been observed 
in approximately 40% of breast cancer patients, but not observed in normal breast tissue58,59. 
Elevated COX signaling has also been positively correlated with several factors related to the 
aggressiveness of breast cancer including tumor size, proliferative rate, and metastasis59,60. These 
factors contribute to overall worse patient outcome, and five-year disease-free survival rates were 
found to be significantly lower in patients with overexpressed COX-2 levels compared to those 
with low COX-2 levels60. The COX and PGE2-stimulated inflammatory response not only creates 
a favorable environment for cancer cell growth and survival, but has also been shown to increase 
chemoresistance in many cancer subtypes61,62. Although the present knowledge concerning the 
role of adipocytes in chemoresistance is limited, current evidence suggests that PGE2, previously 
implicated in promoting obesity-associated inflammation, may also mediate chemoresistance by 
supporting cancer stem cell survival62. This data illustrates the limits of current treatment plans 
and the importance of further research regarding the crosstalk between the adipose tissue and 
cancer cells.  
Effects of Anti-Inflammatory Treatment on Breast Cancer 
COX-1 and COX-2 enzymes have become targets of interest for reducing the effects of 
inflammation in breast cancer progression. When a murine COX-2 knockout mouse line was 
crossed with a MMTV-neu breast cancer model, knockout mice demonstrated significantly 
reduced tumor multiplicity compared to wild-type mice. Subsequently, complete ablation of the 
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COX-2 enzyme in knockout mice reduced tumor burden by 50% and decreased overall tumor sizes 
compared to wild-type mice63. Additional experimental studies have indicated that inhibition of 
COX-1 and COX-2, using specific non-steroidal anti-inflammatory drugs (NSAIDs), is sufficient 
to lower serum prostaglandin levels and decrease the inflammatory burden on the host36. Treatment 
with the NSAID aspirin, in synergy with an anti-PD-1 antibody, promoted both rapid tumor 
regression and eradication of melanoma tumors in mice when compared to anti-PD-1 treatment 
alone65. NSAIDs have even shown potent anti-proliferative results by inducing cell apoptosis in 
many cancer subtypes66–68. Furthermore, the benefits of NSAIDs in clinical oncology have been 
indicated in numerous studies. In colorectal, prostate, and ovarian cancers, epidemiologists have 
identified an inverse relationship between NSAID use and cancer incidence, with significantly 
decreased cancer risk following NSAID treatment69–71. Similar data is also available for breast 
cancer, as studies have indicated that women who regularly consumed the NSAID aspirin are at a 
20% lower risk for developing breast cancer than those who do not consume aspirin72. In addition 
to cancer prevention, studies have also shown that NSAID usage can reduce breast cancer 
recurrence  and chronic low-grade inflammation, particularly among obese women39.  
 Preliminary work in our lab has demonstrated this link between obesity-associated 
inflammation and breast cancer using the NSAID Sulindac, a dual COX-1 and COX-2 inhibitor 
that decreases downstream production of PGE2. Upon analysis, mice fed a DIO (diet-induced 
obesity, 60% kcal from fat) diet exhibited increased tumor growth compared to lean mice fed a 
control (10% kcal from fat) diet, while DIO mice supplemented with 140 ppm Sulindac grew 
tumors no different in size to lean mice. Similarly, Sulindac eliminated the pro-metastatic effects 
of obesity and reduced several known pro-inflammatory factors in the serum of obese mice. These 
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findings suggest a strong link between inflammatory mediators in obesity-associated adipose tissue 
and breast cancer progression. 
Fat Conditioned Media as a Model for the Adipose Secretome  
Current, but limited research investigating the role of adipocytes in the progression of 
numerous cancers have utilized media conditioned from varying adipocyte sources to model the 
adipose secretome in vitro73–78. Adipose explants and subsequent adipose conditioned media are 
often difficult to work with and must be cultured fresh; however, they provide one of the most 
representative methods for studying and characterizing the adipose secretome, and therefore the 
interaction between adipocytes and cancer cells in vitro. Many of the current studies utilizing 
conditioned media use adipose derived stem cells (ASCs), 3T3-L1 adipocytes, or preadipocytes to 
generate their media73–77,79. While these studies have indicated increased proliferative and 
migratory activity of multiple cancer cell lines cultured in conditioned media, the results remain 
inconsistent across multiple different sources and lack generalizability74–78. An additional 
drawback of these studies is that the sources of conditioned media are manipulated to contain 
purified and cultured cells or cell lines, and are thus not representative of the numerous primary 
cell types present in the adipose tissue in vivo74,77–79.   
To more accurately model the link between obesity-associated inflammation and breast 
cancer in vitro, this study will utilize fat-conditioned media (FCM) derived from the mammary fat 
pads of female C57Bl/6 mice fed Control (10% kcal from fat), DIO (diet-induced obesity, 60% 
kcal from fat) or DIO+Sulindac (DIO with 140ppm Sulindac) diets. Unlike ASC, 3T3-L1, or 
preadipocyte conditioned media, FCM contains factors directly secreted from the mammary 
adipose tissue, without further manipulation. It therefore provides a more precise representation of 
the relationship between breast cancer cells and adipose tissue in vitro and allows us to assess the 
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phenotypic differences between diet conditions as they would occur in the mouse. Using FCM and 
multiple metastatic breast cancer cell lines in vitro, this study aims to better illuminate the role of 
obesity-associated inflammation in breast cancer progression and metastasis. Understanding the 
mechanisms that drive this relationship may help break the obesity-cancer link and allow for 






















Goals and Hypothesis 
This project aims to elucidate the mechanisms and specific pro-inflammatory mediators 
through which obesity-associated adipose tissue inflammation promotes breast cancer growth, 
progression, and metastasis using FCM as a model for the adipose secretome in vitro.  
Aim 1. Test the effects of FCM on the metastatic potential of breast cancer cell lines in vitro. 
Multiple metastatic cell lines were cultured in either control, DIO, or DIO+Sulindac FCM. 
Cell line viability and proliferation in response to FCM dosing were assayed using MTT assays. 
Once an effective dose was determined, functional assays using all three FCM conditions were 
performed. Breast cancer cells conditioned with FCM were assayed for classical metastatic 
phenotyping including wound-healing assays.  
Aim 2. Identify pro-inflammatory candidates secreted from mammary adipose tissue that 
drive tumor growth and metastatic potential in the obese state.  
A Luminex bead-based multiplex assay was performed to identify cytokine components 
significantly altered between FCM conditions. FCM was filtered to separate out protein fractions, 
then unfiltered, protein filtrate, and flow-through fractions of FCM were analyzed separately. Gene 
expression and gene set enrichment analyses were completed to identify target pro-inflammatory 
components significantly upregulated in obese mammary adipose tissue compared to lean 
mammary adipose tissue. Subsequent leading edge analysis was conducted to establish hallmark 








Preliminary Animal Study 
180 9-week old female C57BL/6NCrl mice (Charles River Labs, Wilmington, MA) were 
randomized to receive either a Control (10% kcal from fat, D12450J Research Diets) diet or a DIO 
(60% kcal from fat, D12492 Research Diets) diet for 15 weeks. After 15 weeks on diet, the mice 
were randomized to either stay on diet or switch to the same diet supplemented with 140 ppm 
Sulindac for an additional five weeks. Mice were then injected orthotopically into the 4th mammary 
fat pad with 20,000 cells of either E0771, metM-WntLiver, or metM-WntLung metastatic tumor cell 
lines. Mice were palpated for tumor growth and imaged via in vivo IVIS bioluminescent imagining 
to monitor metastasis (PerkinElmer, Akron, OH). Mice were sacrificed when primary tumor size 
reached 1.5cm in any direction. Excised tumors were measured and weighed ex vivo and taken for 
formalin fixation-paraffin embedding (FFPE) to be sectioned for GFP immunohistochemical 
(IHC) staining. Intensity of GFP-IHC stain was quantified to determine overall metastatic burden.  
Generation of FCM 
160 9-week old female C57BL/6NCrl mice (Charles River Labs, Wilmington, MA) were 
randomized to either a Control (10% kcal from fat, D12450J Research Diets) or DIO (diet-induced 
obesity, 60% kcal from fat, D12492 Research Diets) diet.  After 15 weeks, DIO mice were 
randomized to stay on the same diet or switch to a DIO+Sulindac diet (supplemented with 140 
ppm of Sulindac). After 10 weeks, mice were euthanized and mammary fat pads were removed, 
weighed, and resuspended in 2% Fetal Bovine Serum (FBS) cell culture media (RPMI, 2% FBS, 
50U/mL Penicillin/Streptomycin, 0.2mM L-glutamine, 0.01M HEPES buffer). Tissue was minced 
and spun down to remove debris, then resuspended at a final concentration of 100mg adipose tissue 
per 1mL of media (normalized to 100mg for each diet condition). Adipose tissue and media were 
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incubated at 37°C for 24 hours to allow for saturation of secreted factors. Following incubation, 
media was sterile-filtered through a 0.2𝜇𝑚 vacuum filter and stored in 1mL aliquots at -80°C.  
FCM Filtration 
 Control, DIO, and DIO+Sulindac FCM aliquots were thawed on ice and thoroughly mixed 
prior to filtration. The FCM was then divided into two equivalent volumes of 500µL each. One 
500µL aliquot was set aside on ice as the unfiltered FCM, while the other was added to an Amicon 
Ultra-0.5 centrifugal filter (3 kDa membrane size) (Sigma Aldrich, St. Louis, MO) and centrifuged 
at 4°C, 14,000xg for 15 minutes to isolate proteins above 3 kilodaltons in size. Following the initial 
centrifugation, the filtered, deproteinated flow-through was collected and resuspended back to 
500µL with sterile 1X Phosphate Buffered Saline (PBS). The protein filtrate was captured in the 
centrifugal filter was washed three times with 250µL of 1X PBS and centrifuged for 5 minutes at 
14,000xg and 4°C following each subsequent wash. The final, protein-containing filtrate of FCM 
was collected through centrifugation at 10,000xg and 4°C for 3 minutes and resuspended back to 
500µL in PBS. Each unfiltered, filtered flow-through and filtrate fraction was mixed with 2% FBS 
media to the appropriate, dilute concentration. All steps were done on ice or at 4°C. 
Pierce Bicinchoninic Acid (BCA) Total Protein  
 BCA was performed according to manufacturer’s protocol (ThermoFisher Scientific, 
Waltham, MA). Briefly, dilute albumin Bovine Serum Albumin (BSA) standards were prepared 
using stock albumin standard and PBS in triplicate. 0.25𝜇𝐿 of BSA standards, and unfiltered FCM 
samples from each of the Control, DIO, and DIO+Sulindac diet conditions were mixed with 200𝜇𝐿 
of BCA working reagent in a 96 well plate, placed on a plate shaker for 30 seconds, covered, and 
incubated for 30 minutes at 37°C. Absorbance was then read at 562nm on a Cytation 5 Cell 
Imaging Reader (BioTek, Winooski, VT). The blank standard replicate absorbance values were 
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subtracted from each BSA standard and FCM sample absorbance value and plotted as a standard 
curve to determine protein concentration.   
Cell Concentration MTT Assay 
MTT assays were conducted using a progression series of four murine breast cancer cell 
lines, all generated using the MMTV-Wnt1 model. Two nonmetastatic breast cancer lines, E-Wnt 
(basal-like, ER+) and M-Wnt (claudin-low, TNBC) were grown directly from clones taken from 
an MMTV-Wnt1 tumor80, while two metastatic lines, metM-WntLiver, metM-WntLung, were derived 
from the liver and lung metastases following serial transplantation of the nonmetastatic M-Wnt 
cell line into the mammary fat pad of a SCID mouse81. The metM-WntLiver, metM-WntLung, and 
M-Wnt cell lines (2,500 cells per well) were seeded separately in serum restricted, 2% FBS cell 
culture media in 96 well plates and incubated for 24 hours at 37ºC and 5% CO2. Following 
incubation, culture media was replaced with 200µL of either control 2% FBS media, or a 1:10 
dilution of Control, DIO, or DIO+Sulindac FCM in 2% FBS media for an additional 24 hours. 
Media was then aspirated and the cells were stained with 100uL of MTT solution (1:10 dilution of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and 2% cell culture media) for an 
additional 2 hours, covered, and incubated at 37°C and 5% CO2. The MTT reagent was removed, 
100uL of dimethylsulfoxide (DMSO) was added, and the plates were put on a plate shaker for 15 
minutes. Cell viability was recorded using the Cytation 5 Cell Imaging Reader (BioTek, Winooski, 
VT) at 595 and 690nm. Percent viability was calculated using the absorbance of each treatment 
group relative to the 2% FBS media control for that specific treatment/timepoint. Differences 
between groups were assessed using an ANOVA with Tukey’s correction for multiple 
comparisons with p<0.05 significance. 
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Additional 96 well plates of human derived MDA-MB-231 breast cancer cells (10,000 cells 
per well), and metM-WntLiver (25,000 cells per well) were seeded in 2% FBS media and incubated 
for 24 hours at 37ºC and 5% CO2. MetM-WntLung ObR3 (Ob-R shRNA plasmid transfected into 
metM-WntLung cells to generate leptin receptor knockdown cell lines26, 25,000 cells per well) and 
metM-WntLung Con5 (scrambled control shRNA Plasmid transfected into metM-WntLung cells26, 
25,000 cells per well) cell lines were also seeded, but in 2% FBS media with 2𝜇𝑔/𝑚𝐿 Puromycin 
(to maintain plasmid in cell lines), and incubated for 24 hours at 37ºC and 5% CO2.  Media was 
removed and the cells were then treated with 100uL DIO FCM at a 1:20, 1:40, 1:80, 1:160, 1:320, 
1:640, or 1:1280 concentration for either 24 or 48 hours. Subsequent MTT assays with these cell 
lines were conducted using either Control or DIO FCM at 1:10, 1:20, 1:40, 1:80, and 1:160 
concentrations. MTTs were completed following the same procedure listed above.  
Wound-Healing Assay 
 Cell migration chambers (Ibidi, Fitchburg, WI) were placed in each well of a 24 well plate. 
The metM-WntLiver and metM-WntLung metastatic cell lines and the M-Wnt non-metastatic cell line 
(35,000 cells chamber side) were seeded in 2% FBS media with an additional 3mL of 2% FBS 
media surrounding the chambers, and placed in an incubator at 37°C and 5% CO2 for 18-24 hours. 
Subsequent assays using metM-WntLiver, metM-WntLung Obr3, and metM-WntLung Con5 cell lines 
were also completed following the same methods. After cell adherence, the chambers were lifted 
from the wells and the media was aspirated. 1mL of either 2% FBS media, Control, DIO, or 
DIO+Sulindac FCM was added dropwise to each well (as to avoid disturbing attached cell sheets) 
and baseline pictures were taken on an EVOS FL Auto 2 Imaging System (ThermoFisher 
Scientific, Waltham, MA). The plates were returned to the incubator at 37°C and 5% CO2 for an 
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additional 24 hours of treatment. Final images were taken on the EVOS FL Auto 2 Imaging System 
and percent closure was calculated using the MRI Wound Healing Plugin on ImageJ software.  
Luminex Assay 
Luminex assays were performed according to the Novex Multiplex kit manufacturer 
specifications (ThermoFisher Scientific, Waltham, MA) and analyzed on a Luminex MAGPIX 
(Luminex, Austin, TX). Unfiltered, protein filtrate, and flow-through fractions from Control, DIO, 
and DIO+Sulindac FCM diet conditions were prepared in 1:1, 1:2, and 1:4 dilute concentrations 
for the cytokine panel and 1:4, 1:8, and 1:16 dilute concentrations for the diabetes panel. 
Gene Expression Analysis 
 Mammary fat pads contralateral from growing tumor were harvested from lean and obese 
mice. Tissue was flash-frozen and subsequently processed for microarray gene expression analysis 
using Clariom S HT arrays (Affymetrix, Santa Clara, CA). Sample-level gene expression levels 
were generated using TAC 4.0 software (Affymetrix, Santa Clara, CA). Gene Set Enrichment 
Analysis (GSEA) was performed on sample-level data as previously described82,83. Leading edge 


















1. Sulindac reverses the tumor burden and metastatic potential of breast cancer in vivo 
Preliminary work assessing the efficacy of NSAIDs on breast cancer outcomes in obese mouse 
models determined Sulindac to be a compelling treatment option for reducing tumor burden. 
Female C57Bl/6 mice fed DIO and DIO+Sulindac diets exhibited increased weight gain over the 
course of 24 weeks compared to mice fed Control and Control+Sulindac diets (Figure 1A). No 
differences were noted between the Sulindac groups and their non-Sulindac supplemented 
counterparts. DIO mice also demonstrated significantly larger tumor weights compared to the other 
diet group conditions in the metM-WntLiver cell lines (Figure 1B, p<0.001), metM-WntLung (Figure 
1C, p<0.001), and E0771 (Figure 1D, p<0.001) cell lines. The E0771 and metM-WntLiver tumor 
bearing mice on DIO+Sulindac diets grew tumors similar in size to both the Control and 
Control+Sulindac diet groups while the DIO+Sulindac mice with metM-WntLung tumors exhibited 
weights similar in size to only the Control diet. 
Metastatic potential of the mice on each diet was assessed and calculated using total percent 
lung metastases. Mice fed a DIO diet had a significantly greater occurrence of lung metastases 
compared to the other diets in each of the metM-WntLiver (Figure 1E, p<0.001), metM-WntLung 
(Figure 1F, p=0.003), and E0771 (Figure 1G, p=0.008) breast cancer conditions. Mice on the 
DIO+Sulindac diet exhibited metastatic potential similar to the control diet conditions. This data 
suggests that obesity increases tumor burden and metastatic potential across multiple different 











































Figure 1. Control, Control+Sulindac, DIO, and DIO+Sulindac mouse weights measured over a 24 
week time period on diet (A). Ex vivo primary tumor weights measured 4 weeks post injection of 
metM-WntLiver (B), or metM-WntLung (C), E0771 (D) cells. Percentage of lung metastases in 
metM-WntLiver (E), and metM-WntLung (F), E0771 (G) cell lines. Statistical analysis conducted 
















































































































































































































































































































2. Adipose tissue remodeling increases cancer cell proliferation in vitro 
Having demonstrated that diet-induced obesity drives breast cancer progression and metastasis 
but is counteracted by Sulindac treatment in vivo, the mechanisms underlying this relationship 
were further explored using FCM in vitro. As was seen in the previous mouse study, mice that 
were used to generate FCM demonstrated increased weight gain in the DIO and DIO+Sulindac 
diet groups compared to the Control diet group (Figure 3A). Further analysis of the ex vivo 
mammary fat pad weights, shown in Figure 3B, indicate a significant increase in fat pad weight 
for the DIO mice compared to control mice (p<0.0001) and a significant decrease in weight for 
the DIO+Sulindac mice compared to the DIO mice (p<0.0001). Average fat per mouse was 
calculated in Table 1 and fold change differences were determined for the DIO and DIO+Sulindac 
mice compared to the Control mice. These results indicate that the average fat per DIO mouse was 
approximately 6.52 times greater, and per DIO+Sulindac mouse was approximately 5.13 times 
greater than the average Control fat pad weights.  
Protein concentrations were determined for FCM from each diet condition using a BCA assay. 
Although concentrations were similar between all diet conditions, control FCM had the largest 
concentration of protein and DIO+Sulindac FCM had the smallest concentration of protein (Table 
2). These differences may in part be due to the fat pad mass normalization during FCM generation. 
As was indicated in Table 1, the average fat per mouse was much greater in DIO and DIO+Sulindac 
groups compared to Control, yet each FCM condition was normalized to 100mg of fat mass. Due 
to expansion of mass largely due to triglyceride storage and hypertrophy in obese mice, DIO and 
DIO+Sulindac conditions likely had fewer cells per gram of fat mass, which may have contributed 













Figure 3. Mouse weights on Control, DIO, and DIO+Sulindac diets over 8 months (A) and their 
mammary fat pad weights prior to FCM derivation (B). Statistical analysis was conducted using a 










Table 1. Average fat per mouse in each diet group and calculated fold change differences in DIO 
and DIO+Sulindac mice compared to Control mice.  
 



















































































Diet Group Average Fat 
Per Mouse (g) 
Fold 
Change 
Control 0.50155556 1 
DIO 3.2715 6.52270713 




To assess the cell viability of multiple metastatic breast cancer cells following treatment with 
FCM, MTT assays were performed. Initial experiments were conducted using only DIO FCM to 
determine the most effective dosage. Six serial dilutions of FCM starting at a 1:20 concentration 
were completed with MDA-MB-231, metM-WntLiver, metM-WntLung ObR3, and metM-WntLung 
Con5 breast cancer cell lines. Both 24 hour (Figure 4) and 48 hour (Figure 5) treatments were 
assessed and three biological replicates were completed. The 24-hour treatment in Figure 4 
illustrated inconsistencies across the four cell lines, with variability between the biological 
replicates and insignificant differences between concentrations. On the other hand, the 48-hour 
treatment in Figure 5 demonstrated more consistent biological replicates with a similar trend across 
all four cell lines—as the concentration of FCM increased, the cell viability improved, reaching 
peak cell growth at a 1:20 concentration. Although there were varying differences across each cell 
line, all except the metM-WntLung Con5 demonstrated significantly greater cell growth at a 1:20 
FCM concentration compared to the 2% control. These results suggest that longer treatment times 




















Figure 4. Cell viability of MDA-MB-231 (A), metM-WntLiver (B), metM-WntLung ObR3 (C), 
and metM-WntLung Con5 (D) cell lines treated with DIO FCM to assess appropriate 
concentration dosages over a 24 hour time period. Statistical analysis was conducted using a 

















































































































































































































































































   
 
 
   
Figure 5. Cell viability of MDA-MB-231 (A), metM-WntLiver (B), metM-WntLung ObR3 (C), 
and metM-WntLung Con5 (D) cell lines treated with DIO FCM to assess appropriate 
concentration dosages over a 48 hour time period. Statistical analysis was conducted using a 
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The MTT cell viability experiments were repeated using both Control and DIO FCM 
conditions, this time for three 24-hour biological replicates at 1:160, 1:80, 1:40, 1:20, and 1:10 
concentrations. The MDA-MB-231 cell line was excluded from further assays due to growth 
variability and inconsistency. In the metM-WntLiver, metM-WntLung ObR3, and metM-WntLung 
Con5 cell lines, all Control FCM (Figure 6) and DIO FCM (Figure 7) concentrations demonstrated 
significantly increased cell viability compared to the 2% FBS control. Furthermore, treatment with 
DIO FCM exhibited a greater dose-response effect than Control FCM treatment, with the greatest 
increase in cell viability at the 1:10 concentration for the metM-WntLiver (Figure 7A), metM-


















Figure 6. Cell viability of metM-WntLiver (A), metM-WntLung ObR3 (B), and metM-WntLung 
Con5 (C) cell lines treated with Control FCM concentrations for 24 hours. Statistical analysis 






















































































































































































Figure 7. Cell viability of metM-WntLiver (A), metM-WntLung ObR3 (B), and metM-WntLung 
Con5 (C) cell lines treated with DIO FCM concentrations for 24 hours. Statistical analysis 
conducting using a one-way ANOVA with Tukey’s multiple comparisons test.  
 
Given the in vivo mouse study results, a comparison between the Control FCM data in Figure 
6 to the DIO FCM data in Figure 7 was expected to be robust; however, no noteworthy differences 
were observed. We considered that since the FCM was generated directly from the mammary fat 
pads of the mice, it may contain high levels of free fatty acids (especially in DIO FCM), which 
have been previously shown to induce apoptosis in breast cancer cell lines84. We therefore filtered 
the FCM using Amicon Ultra-0.5 filters into protein-containing filtrate and non-protein containing 
flow-through fractions. After filtration, three more MTT biological replicates were conducted 
using Control, DIO and DIO+Sulindac FCM at a 1:10 concentration.  Testing conditions included 
unfiltered FCM, protein filtrate FCM, and flow-through FCM fractions with metM-WntLiver, 
metM-WntLung, and non-metastatic M-Wnt cell lines. The filtered flow-through FCM fractions 
indicated that the filtration was successful for the metM-WntLiver (Figure 8A), metM-WntLung 










































































































































significant difference observed between the diet conditions for all cell lines was a decrease in 
viability of cells treated with DIO FCM filtered flow-through, suggesting that a non-protein 
component was likely decreasing viability of cells treated with the unfiltered DIO FCM as well. 
The unfiltered fractions of each diet condition and for each of the metM-WntLiver (Figure 8D), 
metM-WntLung (Figure 8E), and non-metastatic M-Wnt (Figure 8F) cell lines showed a significant 
increase in cell viability compared to the 2% FBS control. Differences between the unfiltered FCM 
conditions were non-significant for all three cell lines.  
MTT assays utilizing the filtered protein-containing filtrate fractions (Figure 8 G-I) 
demonstrated similar trends to the unfiltered FCM conditions, but with greater differences between 
diet conditions. When metM-WntLung cells were cultured in FCM, the Control-treated cells showed 
significantly increased viability compared to  DIO-treated (p=0.0431), but the other comparisons 
were not (Figure 8H). The M-Wnt cells also exhibited a significant increase in viability in cells 
treated with Control vs DIO FCM (p=0.0086), but again, not for the other conditions (Figure 8I). 
The metM-WntLiver, on the other hand, did not show any significant differences between any diet 











































































































































































































































































































































































































































































































Figure 8. Cell viability for metM-WntLiver (A), metM-WntLung (B), and M-Wnt (C) cell lines 
cultured in  Control, DIO, and DIO+Sulindac filtered FCM flow-through conditions. Cell viability 
for metM-WntLiver (D), metM-WntLung (E), and M-Wnt (F) cell lines cultured in Control, DIO, and 
DIO+Sulindac unfiltered FCM conditions. Cell viability for metM-WntLiver (G), metM-WntLung 
(H), and M-Wnt (I) cell lines cultured in Control, DIO, and DIO+Sulindac filtered FCM filtrate 




Although there were greater observed differences in cell viability between the FCM diet 
conditions for the protein-containing filtrate compared to the unfiltered fraction, the differences 
between diet groups were again not as robust as expected. We therefore questioned how 
representative the quantity of fat used to generate the FCM was of the actual adipose secretome in 
vitro. As was seen in Table 1, the DIO and DIO+Sulindac mice had, on average, more fat per 
mouse than the Control mice; however, the FCM was generating using a normalized 100mg of fat 
per 1mL of media for each diet condition. By treating with FCM generated from a standardized 
mass of fat from each diet group, we were potentially misrepresenting actual growing conditions 
in vivo. In the obese mouse, adjacent tumor cells were exposed to a secretome from a much larger 
adipose depot, and by using a standard amount of fat, our tumor cells cultured in vitro were being 
exposed to lower amounts of secreted factors from DIO FCM than they would be exposed to in 
vivo relative to tumor cells in control mice/FCM. Therefore, additional MTT assays were 
conducted with a 1:10 concentration of Control FCM and a 1:5 concentration of DIO FCM to help 
address this concern (Figure 9). Due to time constraints, only one biological replicate was 
completed; however, initial observations did not reveal the DIO FCM in either unfiltered or protein 
filtrate conditions to be increased compared to Control. Taken together, this data suggests that 
FCM as a model for the adipose secretome in vitro may represent a general relationship between 
the adipose tissue and breast cancer cell proliferation, but may not accurately depict the differences 



































Figure 9. Cell viability for metM-WntLiver (A), metM-WntLung (B), and M-Wnt (C) cell lines 
cultured in 1:10 Control and 1:5 DIO unfiltered conditions. Cell viability for metM-WntLiver (D), 





3. Fat conditioned media drives breast cancer migration in vitro 
 
To assess the impact of the obese microenvironment on tumor cell migration, wound healing 
assays were conducted with metM-WntLiver, metM-WntLung Obr3 (leptin receptor knockdown) and 
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the metM-WntLung Obr3 and metM-WntLung Con5 cells to determine if leptin signaling might play 
a role in differences between FCM treatments. Percent wound closure was calculated using 
representative images of the cell walls prior to FCM treatment (Figure 10A) and following 24 
hours of FCM treatment (Figure 10B). Upon initial analysis of cell migration in DIO FCM of 
varying conditions, it was observed that the metM-WntLung ObR3 (Figure 11B) and metM-WntLung 
Con5 (Figure 11C) cell lines both had significant increases in wound closure compared to the 2% 
FBS control. The metM-WntLiver (Figure 11A), however, did not exhibit any significant differences 
between the 2% FBS control and the FCM conditions, indicating potential cell line differences. 
Interestingly, each increase in FCM concentration for the metM-WntLung ObR3 (Figure 11B) and 
metM-WntLung Con5 (Figure 11C) cell lines demonstrated a decrease in percent wound closure.  
While these decreases were only significant when comparing the 1:20 to 1:5 concentrations, this 









Figure 10. Cell migration of metM-WntLiver cells prior to wound healing (A) and after 24 hours 


























Figure 11. Percent wound closure calculated using ImageJ wound-healing software for metM-
WntLiver (A), metM-WntLung OBR3 (B), and metM-WntLung CON5 (C) cell lines after 24 hour 
treatment with 1:5, 1:10, or 1:20 concentrations of Control FCM. Statistical analysis conducted 
using a one-way ANOVA with Tukey’s multiple comparison test.  
 
Following the initial analysis using DIO FCM at varied concentrations, additional wound 
healing assays were conducted using metM-WntLiver, metM-WntLung, and M-Wnt cell lines 
cultured in a 1:10 concentration of either Control, DIO, or DIO+Sulindac FCM.  Statistical analysis 
revealed the metM-WntLiver (Figure 12A) and metM-WntLung (Figure 12B) cell lines to have 
increased percent wound closure when treated with any of the FCM diet conditions compared to 
the 2% FBS control. The Control and DIO+Sulindac FCM conditions for the M-Wnt cell line 
(Figure 12C), on the other hand, did not show increased wound closure compared to the 2% FBS 
condition. The DIO FCM for the M-Wnt cell line was the only condition that demonstrated an 
increase in percent wound closure (Figure 12C, p=0.0138).  
Despite the variance between cell lines, these wound healing assays are indicative of the 
adipose tissue’s potential role in promoting migration of cancer cells. Although there were no 
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preliminary results establish a prospective foundation for modeling the adipose tissue’s influence 


















Figure 12. Percent wound closure calculated using ImageJ wound-healing software for metM-
WntLiver (A), metM-WntLung (B), and M-Wnt (C) cell lines after 24 hour treatment with Control, 
DIO, or DIO+Sulindac FCM. Statistical analysis conducted using a one-way ANOVA with 
Tukey’s multiple comparison test. 
 
 
4. Pro-inflammatory mediators in obesity-associated adipose tissue may be responsible 
for cancer progression and metastasis 
In order to identify potential pro-inflammatory mediators in obesity-associated adipose tissue 
that may be influencing the previously observed increase in migratory breast cancer phenotypes, 
we conducted gene expression microarray analysis of lean and obese murine mammary fat pads. 
Analysis identified several inflammatory factors in the fat pads that have been identified as 
potential mediators of breast cancer progression and metastasis. Of these identified genes, those 
that were upregulated in DIO mammary fat pads compared to Control included IL-6, CCL9, CCL8, 
CCL6, CCL7, and CCL12 (Table 3). These cytokines are known to play a role in inflammatory 
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growth factor that has been shown to be critical for blood vessel survival (but not growth), was 
found to be downregulated in DIO compared to Control (Table 3)90–92. 
Gene Symbol Fold Change  FDR p-value Gene Description 
IL-6 6.49 0.0126 A inflammatory and immune-suppressive cytokine 
involved in both local and systemic inflammatory 
responses85,87 
CCL9 4.19 0.0256 A chemokine involved in inflammatory responses, cell 
proliferation, and metastasis86,88 
CCL8 7.93 0.0256 Monocyte chemoattractant that recruits inflammatory 
monocytes to target tissues93,94 
CCL6 2.73 0.0439 A chemokine involved in chronic inflammatory 
disorders and macrophage infiltration89,95,96 
VEGFb -3.57 0.0622 A mediator of vascular survival and inhibitor of 
inflammation90,97 
CCL7 6.09 0.0846 Monocyte chemoattractant that promotes the 
recruitment of innate immune cells to sites of 
inflammation93,98,99 
CCL12 3.7 0.0862 A chemokine with roles in embryogenesis and 
hematopoiesis. Released in the tumor 
microenvironment to promote invasion, metastasis and 
epithelial to mesenchymal transition (EMT) 100–102 
Table 3. Inflammatory gene expression fold change differences in DIO compared to control 
mammary fat pads. 
 
To determine which subsets of genes and pathways most significantly contributed to the 
differences in DIO and Control adipose tissue, we conducted gene set enrichment analysis 
(GSEA)82,83.  Upon first assessing broad hallmark pathways upregulated in DIO compared to 
Control mammary fat pads, GSEA revealed four important gene sets: inflammatory responses, 
epithelial to mesenchymal transition, IL-6/JAK/STAT3 signaling, and TNF-𝛼 signaling via the 
inflammatory T-cell regulator, NF-𝜅B (Table 4). The enrichment scores and subsequent gene 
probes for each of these inflammatory pathways were assessed (Figure 13 A,B,C,D). Although 
pinpointing the significance of any one gene in a signature is difficult, further investigation 
revealed IL-6 as a leading edge gene, and thus an important driver of the observed phenotype, in 
all four pathways. CCL7 was also in the leading edge in both the IL-6/JAK/STAT3 and TNF-𝛼 




Hallmark Pathways Normalized Enrichment Score (NES) 
Inflammatory Response 2.1414 
Epithelial to Mesenchymal Transition 2.1123 
IL-6, JAK, STAT3 signaling 2.0827 
TNF-𝜶 signaling via NF-𝜿B 1.8819 
 



































Figure 13. Enrichment plots of hallmark inflammatory response (A), Epithelial to Mesenchymal 
Transition (B), IL-6, JAK, STAT3 signaling (C), and TNF-𝛼 signaling via NF-𝜅B (D) profiles 










Following our results indicating important roles for inflammatory signaling in obesity-
associated adipose tissue, we decided to further probe gene expression in the C7 immunological 
gene sets in GSEA. Additional leading edge analysis of these gene sets implicated IL-6 again as a 
driver gene in 21 of the 182 most significant C7 gene sets (q<0.0001). Of these 21 gene sets, three 
with the highest enrichment scores are listed in Table 5. These three gene sets included genes 
upregulated in T-cells when treated with the pro-inflammatory stimulator IL-21, genes up in 
monocytes stimulated with LPS compared to those treated with an anti-inflammatory drug, and 
genes upregulated in macrophages activated with IFN-𝛼 compared to untreated macrophages. 
These GSEA results using the C7 gene sets clearly point to an inflammatory, activated, type I 
immune program in the obese adipose tissue that is not seen in lean adipose tissue. 






Genes up in T cells when 
activated with pro-
inflammatory IL-21 for 6 hours 





Genes up in LPS treated 






Genes up in IFN𝛼 stimulated 




Table 5. Gene sets, descriptions, and normalized enrichment scores (NES) for gene sets similarly 
altered in DIO fat pads compared to Control fat pads.  
 
 To identify potential protein mediators within the FCM itself, Luminex analyses of 
Control, DIO, and DIO+Sulindac unfiltered, protein filtrate, and filtered flow-through FCM 
fractions were performed. We found relevant cytokine differences between the diet conditions in 
both the unfiltered and protein filtrate fractions, including leptin (Figure 13A), IL-6 (Figure 13B), 
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IL-12 (Figure 13C), G-CSF (Figure 13D), and MCP-1 (Figure 13E). While all cytokines show 
clear differences between Control, DIO and DIO+Sulindac conditions, additional biological 
replicates must be completed before statistical analysis can be completed. The absence of 
cytokines in the filtered flow-through conditions, however, further illustrates the success of the 





















Figure 14. Leptin (A) and cytokine concentrations of IL-6 (B), IL-12 (C), G-CSF (D), and 






























































































































































































































This study investigated the relationship between obesity-associated adipose tissue 
inflammation and breast cancer progression. We first assessed this relationship in vivo with lean, 
obese, and Sulindac-supplemented mice. Our analysis revealed significant differences between the 
diet conditions, specifically in tumor size and metastatic spread. Obese mice exhibited 
significantly larger tumors with greater metastatic burden than lean mice, but these effects were 
counteracted when the obese mice were supplemented with the NSAID Sulindac, as DIO+Sulindac 
mice developed tumors similar in size to lean mice with fewer metastases than DIO mice. 
Importantly, supplementation with Sulindac did not decrease the DIO+Sulindac mouse weights or 
body composition in comparison to the DIO mice, indicating that Sulindac targeted the pro-
tumorigenic and inflammatory effects of obesity, not obesity itself. Our work also agrees with 
previous studies, as Sulindac has been shown to both inhibit 4T1 tumor growth and prolong life 
expectancy of immune-competent mice103. 
To model the obesity-associated adipose secretome in vitro, we generated FCM from the 
mammary fat pads of mice fed Control, DIO, and DIO+Sulindac diets. Initial MTT cell viability 
assays revealed a positive growth trend for increasing DIO FCM concentrations in metM-WntLiver, 
MDA-MB-231, metM-WntLung ObR3, and metM-WntLung Con5 cell lines when treated for 48-
hours. The greatest cell growth was observed in the metM-WntLiver and MDA-MB-231 cell lines 
at a 1:20 FCM concentration. These results suggest that treatment with more concentrated FCM 
may drive greater cell growth. No significant differences between FCM concentrations and the 2% 
FBS control were noted in the 24-hour treatment, indicating that cells may require prolonged 
treatment before the effects of FCM can be observed.  
Given the results of the initial MTT assays at varying FCM concentrations, additional 
experiments were conducted using both DIO and Control FCM to begin targeting phenotypic 
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differences between the diet conditions. No dose-response effect was observed between the 
increasing Control FCM concentrations in the metM-WntLung ObR3 and metM-WntLung Con5 cell 
lines, but a significant dose-response effect was observed in the metM-WntLiver cell line. On the 
other hand, treatment with DIO FCM showed a significant dose-response effect in all three cell 
lines. Most notably, the 1:10 DIO FCM concentration exhibited the greatest cell viability, again 
suggesting that treatment with more concentrated FCM increases cell growth. The dose-response 
effect observed between concentrations in the DIO FCM may suggest an increased concentration 
of pro-tumorigenic factors in the obese state that may aid in driving tumor growth and progression. 
Our previous in vivo work illustrated robust differences between mice on Control and DIO 
diets, therefore leading us to believe that similar trends may be observed in vitro. Despite the 
greater dose-response effect seen in the DIO MTT assays compared to the Control, there were no 
observed phenotypic differences between cells treated with control and DIO FCM. One potential 
factor that may have contributed to these results is the toxicity of excess fatty acids present in the 
FCM. Numerous studies have implicated fatty acids as promoters of apoptosis, thereby decreasing 
cell proliferation and survival of many cancer subtypes104,105. Furthermore, fatty acids have even 
been shown to directly suppress breast cancer growth by decreasing viability and proliferation105. 
Excess fatty acids in the FCM may therefore have impaired cell growth, confounding an accurate 
comparison of the DIO and Control conditions.   
In an effort to minimize the effect of fatty acids, Control, DIO, and DIO+Sulindac FCM 
were filtered through Ultra-0.5 microcentrifuge 3 kDa protein filters and subsequent cell viability 
assays were conducted. Filtration efficacy was verified using BCA protein content analysis. These 
findings were again verified with an MTT assay using filtered FCM flow-through to treat the cells, 
as decreased cell growth was observed for each diet condition when compared to the unfiltered 
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FCM. Interestingly, the only filtered FCM flow-through fraction that differed from the 2% FBS 
control was DIO. This supports our hypothesis regarding higher fatty acid content in the unfiltered 
DIO FCM compared to the other diets, as the flow-through fraction in the DIO FCM should have 
a high concentration of free fatty acids. 
Contrary to what was expected following filtration, assessment of the FCM protein filtrate 
revealed a decrease in cell growth for cells treated with DIO FCM compared to Control.  While 
the excess fatty acids may still have contributed to toxicity in the initial MTT assays, the filtered 
data suggests that there may have been other factors leading to a lack of congruency between FCM 
and in vivo data for Control, DIO, and DIO+Sulindac comparisons. One such limitation that may 
have contributed to these findings stems from the generation of FCM. When generated, each FCM 
diet condition was normalized to 100mg of fat pad mass rather than the average fat per mouse. As 
DIO and DIO+Sulindac mammary fat pads had much greater average weight than the mammary 
fat pads from Control mice, it is expected that they would also experience a greater amount of fat-
secreted factors in the adipose tissue secretome. In fact, the fat pads of DIO mice were on average 
6.52 times more massive than the Control, and the fat pads of DIO+Sulindac mice were 5.13 times 
more massive than the Control. Normalizing the FCM to fat pad mass may therefore have 
contributed to a loss of these factors in the DIO and DIO+Sulindac conditions, as we were 
effectively treating our cells with 1/5-1/6 of what they would’ve been exposed to in vivo relative 
to control mice. This may explain the lack of differences seen between the FCM diet conditions 
and may have limited the ability to model the adipose tissue secretome in vitro.  
To assess the validity of this limitation, an MTT assay utilizing a 1:5 DIO FCM 
concentration alongside a 1:10 Control FCM concentration was conducted. Analysis indicated no 
observable differences between the Control and DIO filtered FCM filtrate conditions. However, 
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when in previous MTTs using 1:10 for both DIO and Control FCM, we had noted a significant 
decrease in viability of cells treated with DIO FCM. Thus, it makes sense that although we did not 
see significant differences, we were increasing viability of the cells by increasing concentration of 
the DIO FCM. Additional biological replicates and ongoing studies are underway to further 
investigate this limitation, specifically with concentrations of DIO and DIO+Sulindac FCM that 
mimic the respective 6.52- and 5.13-fold changes. By normalizing the FCM to these fold changes, 
we hope to better model the adipose secretome, and all of its secreted factors, in each diet condition 
as it would occur in vivo. 
Similar effects to those observed with cell proliferation were seen with migration and 
metastatic potential assessed using wound-healing assays.  A significant increase in percent wound 
closure was noticed for two of the three metastatic breast cancer cell lines when treated with FCM 
compared to the 2% FBS control, indicating the role of FCM and the adipose tissue secretome on 
driving cell migration. These results agree with evidence of the obese microenvironment 
promoting breast cancer migration and metastasis, as seen in our previous in vivo work with 
Sulindac. Additionally, this observed increase in cell migration may be attributed to the adipose 
secretome and its secretion of pro-inflammatory cytokines. These findings can be better explained 
by current literature regarding secretome analysis of breast cancer-associated adipose tissue. 
Several studies have shown the pro-migratory effect of the adipose-tissue secretome, indicating 
that the composition of the secretory profile has the ability to promote breast cancer 
metastasis106,107.  
Like the MTT assays, however, the wound-healing assays revealed no significant 
differences between the Control, DIO, and DIO+Sulindac diet conditions. Again, these results may 
be in part due to the normalization to fat pad mass rather than average fat per mouse during FCM 
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generation. In addition to the limitations presented by fat pad mass normalization, the wound-
healing assays were also impacted by faulty migration chambers—many of the replicates had cells 
growing under the chamber walls prior to FCM treatment. This may have affected the average 
percent wound closure for each diet condition, altering the results and statistical analysis. Further 
experimentation is ongoing with scratch wound-healing assays to mitigate this problem.  
To study the role that specific mediators may play in the obesity-breast cancer link, gene 
expression analysis was performed. This assay revealed several pro-inflammatory mediators that 
may be responsible for promoting the phenotypic changes seen in obesity-associated breast cancer. 
More specifically, analysis of gene expression differences upregulated in DIO compared to Control 
mammary adipose tissue highlighted many pro-inflammatory cytokines. These cytokines included 
IL-6, CCL7 and CCL9, three well established mediators in cancer progression and metastasis85–88. 
The CCL chemokines, specifically CCL8, have even been shown to promote breast cancer 
tumorigenesis and induce metastatic spread in both human and mouse models108. These findings 
suggest a pro-inflammatory and pro-oncogenic role of obesity-associated adipose tissue. 
Furthermore, this gene expression analysis revealed decreased VEGFb concentrations in the DIO 
fat pads compared to Control. As an endothelial growth factor with an important role in 
maintaining vascular health, VEGFb has been shown to inhibit obesity-associated inflammation 
and improve metabolic health in murine models97. The potential anti-inflammatory properties of 
VEGFb would thereby support the decreased levels observed in obese mammary fat pad conditions 
and strengthen the argument that obesity-associated adipose tissue is pro-inflammatory in nature. 
Many of these cytokines identified in the preliminary gene expression analysis were also 
implicated in subsequent gene set expression analysis, specifically IL-6 and CCL7. Moreover, 
these cytokines were highly enriched in hallmark pathways upregulated in DIO compared to 
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control mammary fat pads, including inflammatory response, epithelial to mesenchymal transition, 
IL-6/JAK/STAT3 signaling, and TNF-𝛼 signaling via NF-𝜅B pathways. The upregulation of these 
pathways in obese fat pads further strengthens the claim that inflammation plays a critical role in 
driving obesity-associated phenotypes. More specifically, these pathways may also highlight the 
relationship between obesity-associated inflammation and tumorigenesis. For example, the 
regulation of  NF-𝜅B by TNF-𝛼 has been well-established in both inflammation and oncogenesis 
as NF-𝜅B plays a critical role in in the expression of pro-inflammatory genes that promote tumor 
growth109,110. The epithelial to mesenchymal transition is also a well-supported hallmark of 
carcinogenesis and metastatic spread; however, it has recently been discovered that EMT programs 
may also stimulate the production of pro-inflammatory factors by cancer cells, and conversely be 
induced by tumor-initiated inflammation27,111,112.   
The involvement of IL-6 as a leading edge gene in all four of the hallmark pathways led us 
to pursue the immunological gene set, C7. Of the 182 most significant immune gene sets 
upregulated in DIO mammary fat pads compared to control, IL-6 was listed as a leading edge gene 
in 21. These gene sets included a comparison of anti-TREM1 and LPS treated monocytes. As an 
anti-inflammatory immunoreceptor, anti-TREM1 has been shown to reduce inflammation and 
oxidative stress in mice113. The positive normalized enrichment score equating the down-
regulation of IL-6 in anti-TREM1 to the upregulation of IL-6 in the DIO fat pads therefore signifies 
the important pro-inflammatory role of IL-6 in the obese state. Furthermore, the similarity between 
the down-regulation of a pro-inflammatory cytokine in an anti-inflammatory condition such as 
anti-TREM1 to the upregulation of the same cytokine in obese fat pads may suggest the potential 
role for NSAID treatments in reducing the pro-inflammatory effects of the obese state.  
Lydia Eisenbeis 
 45 
Additional immune gene sets investigated with IL-6 in the leading edge included IFN𝛼-
stimulated macrophages and T cells treated with IL-21 for 6 hours. As a type I interferon, IFN𝛼 is 
an antiviral cytokine that may be central to the initiation of inflammatory responses, specifically 
in the lung, by recruiting and activating immune cells114. In addition, activation of IFN𝛼 signaling 
within the local tumor microenvironment has been shown to contribute to increased cancer cell 
migration and drug resistance in breast cancer patients115. IL-21 has also been indicated as a pro-
inflammatory cytokine with oncogenic properties116. In MDA-MB-231 breast cancer cells treated 
with IL-21, increased invasion and migratory characteristics were observed. Further suppression 
of the IL-21 receptor by gene silencing spontaneously decreased breast cancer cell proliferation, 
indicating its role in cancer cell progression117. The similar overexpression of IL-6 in macrophages 
stimulated by IFN𝛼, macrophages treated for 6 hours with IL-21, and our DIO mammary fat pads 
further elucidates the pro-inflammatory properties of the obese mammary fat pads with IL-6 as an 
important driver.  
Investigation of potential pro-inflammatory mediators in the FCM using a Luminex assay 
also revealed IL-6 was as a target cytokine. Although only one biological replicate was completed, 
a clear trend in levels of IL-6 were observed between the FCM conditions, with increased 
concentrations in the DIO compared to both Control and DIO+Sulindac FCM. Importantly, IL-6 
is a known product of PGE2, a prostaglandin involved in producing inflammatory cytokines55,63,87. 
Furthermore, COX-1 and COX-2, the main enzymes responsible for production of PGE2, are 
directly inhibited by the NSAID Sulindac. As a dual COX-1 and COX-2 inhibitor, Sulindac 
thereby acts to decrease prostaglandin synthesis, thus blocking its production of IL-6 and other 
pro-inflammatory cytokines. PGE2’s suggested link to increased metastatic potential and poor 
prognosis in obese breast cancer patients indicates the public health significance of this study and 
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the potential for Sulindac and other NSAIDs as treatment options for obesity-associated cancer 
progression118,119. Further replicates are necessary, however, to make any concrete conclusions. 
The Luminex assay also revealed Leptin and G-CSF as target pro-inflammatory cytokines. 
Leptin, a known mediator of breast cancer progression in the obese state, demonstrated differences 
between the unfiltered DIO FCM compared to the unfiltered Control FCM. Subsequently, the 
DIO+Sulindac FCM indicated a potentially lower concentration of Leptin compared to the DIO, 
although non-significant due to lack of biological replicates. As Leptin has been thoroughly 
indicated in the literature as a known growth factor involved in the proliferation, invasion, and 
migration of breast cancer cells, our data suggest that its potential increase in the obese state may 
implicate it as a possible driver of tumorigenesis. Additional replicates, however, are necessary to 
support this claim120.  G-CSF, a granulocyte colony-stimulating factor that stimulates bone marrow 
secretion of granulocytes and stem cells, was found to have varying concentrations in all diet 
conditions. Known to play a role in anti-tumor immune responses, G-CSF is capable of promoting 
proper immune function to fight off cancer cell invasion. Therefore, non-obese, lean conditions 
may be more effective at promoting anti-tumor immunity than obese conditions. G-CSF has also 
been used in some cancers to accelerate recovery and reduce mortality as it can boost anti-tumor 
immune responses121. The potential decrease of G-CSF in DIO and DIO+Sulindac FCM conditions 
indicates the possible tumor promoting and immune suppressing role of the obese state. The 
similarity between the DIO and DIO+Sulindac conditions poses an interesting question about the 
role of G-CSF in mediating Sulindac’s potential to increase anti-tumor immunity; however, further 
experimentation is required to assess this claim. 
 Taken together, these results provide preliminary evidence for the hypothesis that obesity-
associated inflammation alters the adipose secretome, thereby augmenting breast cancer growth 
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and metastatic potential. Ongoing work is being completed to assess the stem-cell enrichment 
capabilities of FCM conditions using mammosphere formation assays. Pro-inflammatory 
mediators such as those previously discussed may also be further analyzed using receptor 
inhibition, antibody neutralization, and direct component supplementation to verify that target 
components are both necessary and sufficient to promote a pro-metastatic phenotype. Considering 
the complexity of the tumor microenvironment, our experimental analysis of FCM treated breast 
cancer cells only addresses one component of this microenvironment. Additional work may 
therefore include the assessment of T cells treated with varied FCM conditions to determine 
whether FCM can affect activation, proliferation, or tumor-killing ability of T cells. Regarding the 
previously listed limitations, future directions are primarily focused on identifying the correct 
methods and concentrations for assessing FCM in vitro.  
Our current and ongoing work also suggests a potential avenue for combination therapies 
using NSAIDs and chemotherapeutics together. Considering the current evidence implicating 
PGE2 as a potential mediator in chemoresistance, Sulindac may provide important anti-
inflammatory mechanisms that increase the efficacy of chemotherapies to many cancer subtypes62. 
Several studies have even indicated the role of NSAIDs in sensitizing cancer cells to the anti-
proliferative effects of cytotoxic drugs, thereby supporting its potential role in clinical 
applications122. Future directions may thus include assessment of chemotherapies on breast cancer 
cells cultured with control, DIO, and DIO+Sulindac FCM conditions.  
Further research is needed to examine the precise mechanisms driving the relationship 
between obesity-associated adipose tissue and breast cancer, but the findings of this study indicate 
potential pro-inflammatory mechanistic drivers, as well as a prospective anti-inflammatory 






This study provides evidence that the obesity-associated adipose tissue secretome, modeled 
by FCM, may impact the proliferative and metastatic potential of several breast cancer cell lines 
through increased levels of pro-inflammatory cytokines. Supplementation with Sulindac mediates 
the tumorigenic and inflammatory response of obesity-associated adipose tissue, potentially by 
modulating expression of IL-6, highlighting its importance as a potential treatment option to 
counteract the obesity-driven inflammatory response and to limit the increased risk of cancer 
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